Cite
HARVARD Citation
Griffith, D. et al. (n.d.). 401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects. Open forum infectious diseases. pp. S154-S155. [Online].